{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:13:15Z","timestamp":1770149595093,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,28]]},"DOI":"10.7759\/cureus.100247","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T13:29:10Z","timestamp":1766928550000},"source":"Crossref","is-referenced-by-count":1,"title":["Inhaled Insulin Decoded: Dispelling Myths and Presenting Clinical Evidence"],"prefix":"10.7759","author":[{"given":"Jothydev","family":"Kesavadev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant  P","family":"Thacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeta","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Asirvatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharat","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramila","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehla","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameya","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayashree","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Bhograj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piya Ballani","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilnathan","family":"Mohanasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sugumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Karuppan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024, 403:2204-56. 10.1016\/S0140-6736(24)00685-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666230413094200","article-title":"Prevalence of diabetes in India: a review of IDF Diabetes Atlas 10th edition","volume":"20","author":"Kumar A","year":"2024","unstructured":"Kumar A, Gangwar R, Zargar AA, Kumar R, Sharma A. Prevalence of diabetes in India: a review of IDF Diabetes Atlas 10th edition. Curr Diabetes Rev. 2024, 20:e130423215752. 10.2174\/1573399819666230413094200","journal-title":"Curr Diabetes Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0472-0","article-title":"AFREZZA\u00ae (insulin human) inhalation powder: a Review in diabetes mellitus","volume":"75","author":"Kim ES","year":"2015","unstructured":"Kim ES, Plosker GL. AFREZZA\u00ae (insulin human) inhalation powder: a Review in diabetes mellitus. Drugs. 2015, 75:1679-86. 10.1007\/s40265-015-0472-0","journal-title":"Drugs"},{"key":"ref4","unstructured":"The Diabetes Atlas. (2025). Accessed. August 29, 2025: https:\/\/diabetesatlas.org."},{"key":"ref5","unstructured":"IDF India. (2025). Accessed. August 29, 2025: https:\/\/idf.org\/our-network\/regions-and-members\/south-east-asia\/members\/india\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/cmi.cmi_47_17","article-title":"Practical use of insulin in diabetes mellitus","volume":"15","author":"Shetty S","year":"2017","unstructured":"Shetty S, Daniel R, Thomas N. Practical use of insulin in diabetes mellitus. Current Medical Issues. 2017, 15:177-85. 10.4103\/cmi.cmi_47_17","journal-title":"Current Medical Issues"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.33.4.175","article-title":"Therapeutic options for the management of postprandial glucose in patients with type 2 diabetes on basal insulin","volume":"33","author":"Hinnen DA","year":"2015","unstructured":"Hinnen DA. Therapeutic options for the management of postprandial glucose in patients with type 2 diabetes on basal insulin. Clin Diabetes. 2015, 33:175-80. 10.2337\/diaclin.33.4.175","journal-title":"Clin Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/cd20-0117","article-title":"Exploring the burden of mealtime insulin dosing in adults and children with type 1 diabetes","volume":"39","author":"Lane W","year":"2021","unstructured":"Lane W, Lambert E, George J, Rathor N, Thalange N. Exploring the burden of mealtime insulin dosing in adults and children with type 1 diabetes. Clin Diabetes. 2021, 39:347-57. 10.2337\/cd20-0117","journal-title":"Clin Diabetes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2019.01.004","article-title":"Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: a Canadian perspective","volume":"43","author":"Senior P","year":"2019","unstructured":"Senior P, Hramiak I. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: a Canadian perspective. Can J Diabetes. 2019, 43:515-23. 10.1016\/j.jcjd.2019.01.004","journal-title":"Can J Diabetes"},{"key":"ref10","article-title":"Regular Insulin","author":"Munguia C","year":"2025","unstructured":"Munguia C, Correa R. Regular Insulin. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.07.005","article-title":"Evolution of insulin: from human to analog","volume":"127","author":"Tibaldi JM","year":"2014","unstructured":"Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014, 127:S25-38. 10.1016\/j.amjmed.2014.07.005","journal-title":"Am J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot M","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012, 29:682-9. 10.1111\/j.1464-5491.2012.03605.x","journal-title":"Diabet Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1932296814555820","article-title":"Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties","volume":"8","author":"Klonoff DC","year":"2014","unstructured":"Klonoff DC. Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties. J Diabetes Sci Technol. 2014, 8:1071-3. 10.1177\/1932296814555820","journal-title":"J Diabetes Sci Technol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01760-5","article-title":"Safety and efficacy of inhaled Technosphere\u00ae insulin in the postprandial period with modified initial dose conversion","volume":"16","author":"Jacobson C","year":"2025","unstructured":"Jacobson C, Kaiserman KB, Ulloa J, et al.. Safety and efficacy of inhaled Technosphere\u00ae insulin in the postprandial period with modified initial dose conversion. Diabetes Ther. 2025, 16:1695-705. 10.1007\/s13300-025-01760-5","journal-title":"Diabetes Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443120-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of inhaled insulin","volume":"43","author":"Patton JS","year":"2004","unstructured":"Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004, 43:781-801. 10.2165\/00003088-200443120-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/rr58","article-title":"The lung as a route for systemic delivery of therapeutic proteins and peptides","volume":"2","author":"Agu RU","year":"2001","unstructured":"Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001, 2:198-209. 10.1186\/rr58","journal-title":"Respir Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.06.025","article-title":"Inhaled insulin: a breath of fresh air? A review of inhaled insulin","volume":"36","author":"Santos Cavaiola T","year":"2014","unstructured":"Santos Cavaiola T, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014, 36:1275-89. 10.1016\/j.clinthera.2014.06.025","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01039.x","article-title":"Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin","volume":"11","author":"Rave K","year":"2009","unstructured":"Rave K, Potocka E, Heinemann L, et al.. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009, 11:715-20. 10.1111\/j.1463-1326.2009.01039.x","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/193229680800200206","article-title":"Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes","volume":"2","author":"Rave K","year":"2008","unstructured":"Rave K, Heise T, Heinemann L, Boss AH. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008, 2:205-12. 10.1177\/193229680800200206","journal-title":"J Diabetes Sci Technol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0478","article-title":"Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes","volume":"30","author":"Rave K","year":"2007","unstructured":"Rave K, Heise T, Pf\u00fctzner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care. 2007, 30:2307-8. 10.2337\/dc07-0478","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0315","article-title":"Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents","volume":"31","author":"Rosenstock J","year":"2008","unstructured":"Rosenstock J, Bergenstal R, Defronzo RA, et al.. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008, 31:2177-82. 10.2337\/dc08-0315","journal-title":"Diabetes Care"},{"key":"ref22","unstructured":"Study shows AFREZZA(R) controls blood sugar levels in type 1 diabetes, results in weight loss, less hypoglycemia than usual care. (2025). Accessed. October 20, 2025: https:\/\/investors.mannkindcorp.com\/node\/8711\/pdf."},{"key":"ref23","unstructured":"CDSCO approves Afrezza\u00ae (insulin human) inhalation powder in India. (2025). Accessed. June 16, 2025: https:\/\/investors.mannkindcorp.com\/node\/20171\/pdf."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00958-8","article-title":"Comprehensive pulmonary safety review of inhaled Technosphere\u00ae Insulin in patients with diabetes mellitus","volume":"40","author":"McGill JB","year":"2020","unstructured":"McGill JB, Peters A, Buse JB, Steiner S, Tran T, Pompilio FM, Kendall DM. Comprehensive pulmonary safety review of inhaled Technosphere\u00ae Insulin in patients with diabetes mellitus. Clin Drug Investig. 2020, 40:973-83. 10.1007\/s40261-020-00958-8","journal-title":"Clin Drug Investig"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0629","article-title":"Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-na\u00efve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Franco D, Korpachev V, et al.. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-na\u00efve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015, 38:2274-81. 10.2337\/dc15-0629","journal-title":"Diabetes Care"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01500.x","article-title":"Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabetes treatment: a randomized trial","volume":"14","author":"Raskin P","year":"2012","unstructured":"Raskin P, Heller S, Honka M, Chang PC, Boss AH, Richardson PC, Amin N. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012, 14:163-73. 10.1111\/j.1463-1326.2011.01500.x","journal-title":"Diabetes Obes Metab"},{"key":"ref27","unstructured":"Afrezza. safety information. (2025). Accessed: July 28, 2025: https:\/\/afrezzahcp.com\/safety\/."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.08.151","article-title":"Afrezza-induced pulmonary infiltrate.","volume":"156","author":"Parthvi R","year":"2019","unstructured":"Parthvi R, Mehra S. Afrezza-induced pulmonary infiltrate.. Chest. 2019, 156:51. 10.1016\/j.chest.2019.08.151","journal-title":"Chest"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/193229681200600406","article-title":"Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin","volume":"6","author":"Boss AH","year":"2012","unstructured":"Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012, 6:773-9. 10.1177\/193229681200600406","journal-title":"J Diabetes Sci Technol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01084-0","article-title":"Comparison of pharmacokinetics and pharmacodynamics of inhaled Technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus","volume":"61","author":"Grant M","year":"2022","unstructured":"Grant M, Heise T, Baughman R. Comparison of pharmacokinetics and pharmacodynamics of inhaled Technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus. Clin Pharmacokinet. 2022, 61:413-22. 10.1007\/s40262-021-01084-0","journal-title":"Clin Pharmacokinet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311666160829144240","article-title":"Safety of Technosphere inhaled insulin","volume":"12","author":"Mikhail N","year":"2017","unstructured":"Mikhail N. Safety of Technosphere inhaled insulin. Curr Drug Saf. 2017, 12:27-31. 10.2174\/1574886311666160829144240","journal-title":"Curr Drug Saf"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320960420","article-title":"Long-term nonclinical pulmonary safety assessment of Afrezza, a novel insulin inhalation powder","volume":"49","author":"Greene SF","year":"2021","unstructured":"Greene SF, Nikula KJ, Poulin D, McInally K, Reynolds JA. Long-term nonclinical pulmonary safety assessment of Afrezza, a novel insulin inhalation powder. Toxicol Pathol. 2021, 49:334-48. 10.1177\/0192623320960420","journal-title":"Toxicol Pathol"},{"key":"ref33","unstructured":"AFREZZA\u00ae (insulin human) inhalation powder. (2014). Accessed. June 16, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022472lbl.pdf."},{"key":"ref34","unstructured":"FDA briefing document. (2017). Accessed. July 20, 2025: https:\/\/fda.report\/media\/108291\/FDA-Briefing-Information-for-the-October-18-2017-Meeting-of-the-Endocrinologic-and-Me.."},{"key":"ref35","unstructured":"AFREZZA\u00ae prescribing information. (2023). Accessed. September 1, 2025: https:\/\/afrezza.com\/wp-content\/uploads\/2023\/02\/Full-Prescribing-Information-Feb-2023.pdf."},{"key":"ref36","article-title":"Afrezza (insulin human) inhalation powder: a new inhaled insulin for the management of type-1 or type-2 diabetes mellitus","volume":"40","author":"Goldberg T","year":"2015","unstructured":"Goldberg T, Wong E. Afrezza (insulin human) inhalation powder: a new inhaled insulin for the management of type-1 or type-2 diabetes mellitus. Drug Forecast. 2015, 40:735-41.","journal-title":"Drug Forecast"},{"key":"ref37","unstructured":"MannKind announces U.S. FDA accepts for review its supplemental Biologics License Application (sBLA) for inhaled insulin (Afrezza) in children and adolescents aged 4-17 years living with diabetes. (2025). Accessed. December 5, 2025: https:\/\/investors.mannkindcorp.com\/node\/20791\/pdf."},{"key":"ref38","unstructured":"Afrezza\u00ae INHALE-1 Study in Pediatrics (INHALE-1). (2021). Accessed. September 1, 2025: https:\/\/www.clinicaltrials.gov\/study\/NCT04974528."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0075","article-title":"Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial","volume":"38","author":"Bode BW","year":"2015","unstructured":"Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015, 38:2266-73. 10.2337\/dc15-0075","journal-title":"Diabetes Care"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.11.002","article-title":"Results of a 24-week trial of Technosphere insulin versus insulin aspart in type 2 diabetes","volume":"27","author":"Hoogwerf BJ","year":"2021","unstructured":"Hoogwerf BJ, Pantalone KM, Basina M, Jones MC, Grant M, Kendall DM. Results of a 24-week trial of Technosphere insulin versus insulin aspart in type 2 diabetes. Endocr Pract. 2021, 27:38-43. 10.1016\/j.eprac.2020.11.002","journal-title":"Endocr Pract"},{"key":"ref41","article-title":"Inhaled insulin: extending the horizons of inhalation therapy","volume":"52","author":"Guntur VP","year":"2007","unstructured":"Guntur VP, Dhand R. Inhaled insulin: extending the horizons of inhalation therapy. Respir Care. 2007, 52:911-22.","journal-title":"Respir Care"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v7.i20.599","article-title":"Place of Technosphere inhaled insulin in treatment of diabetes","volume":"7","author":"Mikhail N","year":"2016","unstructured":"Mikhail N. Place of Technosphere inhaled insulin in treatment of diabetes. World J Diabetes. 2016, 7:599-604. 10.4239\/wjd.v7.i20.599","journal-title":"World J Diabetes"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20150892","article-title":"A novel rapid-acting oral inhalation human insulin for diabetes mellitus: Afrezza","volume":"4","author":"Beedimani RS","year":"2016","unstructured":"Beedimani RS, Shetkar SG. A novel rapid-acting oral inhalation human insulin for diabetes mellitus: Afrezza. Int J Basic Clin Pharmacol . 2016, 4:1040-2. 10.18203\/2319-2003.ijbcp20150892","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.10.004","article-title":"Ultra rapid-acting inhaled insulin improves glucose control in patients with type 2 diabetes mellitus","volume":"27","author":"Levin P","year":"2021","unstructured":"Levin P, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra rapid-acting inhaled insulin improves glucose control in patients with type 2 diabetes mellitus. Endocr Pract. 2021, 27:449-54. 10.1016\/j.eprac.2020.10.004","journal-title":"Endocr Pract"},{"key":"ref45","article-title":"Inhaled insulin for controlling blood glucose in patients with diabetes","volume":"3","author":"Silverman BL","year":"2007","unstructured":"Silverman BL, Barnes CJ, Campaigne BN, Muchmore DB. Inhaled insulin for controlling blood glucose in patients with diabetes. Vasc Health Risk Manag. 2007, 3:947-58.","journal-title":"Vasc Health Risk Manag"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2337\/db25-833-P","article-title":"Efficacy and safety of prandial Technosphere inhaled insulin (Afrezza) compared with placebo in adult individuals with T2DM-results from a phase III clinical trial from India. 833-P","volume":"74","author":"Prasanna Kumar KM","year":"2025","unstructured":"Prasanna Kumar KM, Rama Mohan MV, Gupta H, et al.. Efficacy and safety of prandial Technosphere inhaled insulin (Afrezza) compared with placebo in adult individuals with T2DM-results from a phase III clinical trial from India. 833-P. Diabetes. 2025, 74:1. 10.2337\/db25-833-P","journal-title":"Diabetes"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0582","article-title":"Inhaled Technosphere insulin plus insulin degludec for adults with type 1 diabetes: the INHALE-3 Extension study","volume":"27","author":"Beck RW","year":"2025","unstructured":"Beck RW, Bailey RJ, Klein KR, et al.. Inhaled Technosphere insulin plus insulin degludec for adults with type 1 diabetes: the INHALE-3 Extension study. Diabetes Technol Ther. 2025, 27:170-8. 10.1089\/dia.2024.0582","journal-title":"Diabetes Technol Ther"},{"key":"ref48","article-title":"Pulmonary Function Tests","author":"Ponce MC","year":"2025","unstructured":"Ponce MC, Sankari A, Sharma S. Pulmonary Function Tests. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433904-inhaled-insulin-decoded-dispelling-myths-and-presenting-clinical-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T13:29:13Z","timestamp":1766928553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433904-inhaled-insulin-decoded-dispelling-myths-and-presenting-clinical-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.100247","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,28]]}}}